BIO vs TXG: stock comparison and AI forecast
Bio-Rad Laboratories, Inc. (BIO) and 10x Genomics, Inc. (TXG) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BIO Bio-Rad Laboratories, Inc.
- Market Cap
- $10.02B
- P/E Ratio
- 45.8x
- Size
- large-cap
- AI Forecast
TXG 10x Genomics, Inc.
- Market Cap
- $8.03B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BIO is 1.2 times larger than TXG by market capitalization ($10.02B against $8.03B).
- BIO turns 8.6% of its revenue into net income, against -12.2% for TXG.
- BIO carries 0.43 times debt per unit of equity, against 0.25 times for TXG.
- Both companies share the SEC industry classification Laboratory Analytical Instruments.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BIO | TXG |
|---|---|---|
| Market Cap | $10.02B | $8.03B |
| P/E Ratio | 45.77x | – |
| P/B Ratio | 1.40x | 9.73x |
| EPS | $8.19 | $-0.49 |
| Book Value/Share | $268.30 | $6.34 |
| Revenue/Share | $96.84 | $4.73 |
| FCF/Share | $13.21 | $0.93 |
Profitability & Margins
| Metric | BIO | TXG |
|---|---|---|
| ROE | 3.1% | -9.1% |
| ROA | 2.2% | -7.3% |
| ROIC | 0.6% | -9.7% |
| Gross Margin | 51.9% | 70.0% |
| Operating Margin | 2.0% | -14.3% |
| Net Margin | 8.6% | -12.2% |
| EBT Margin | 13.5% | -12.1% |
| Tax Rate | 36.5% | -0.3% |
Financial Health
| Metric | BIO | TXG |
|---|---|---|
| Current Ratio | 3.14x | 5.69x |
| Quick Ratio | 2.33x | 5.25x |
| D/E Ratio | 0.43x | 0.25x |
| Financial Leverage | 1.43x | 1.25x |
| Interest Coverage | 6.0x | -6898.5x |
| Working Capital | $2.06B | $556M |
Cash Flow
| Metric | BIO | TXG |
|---|---|---|
| Operating Cash Flow | $493M | $127M |
| Free Cash Flow | $353M | $121M |
| Capital Spending | -$140M | -$6M |
| OCF Growth YoY | -7.8% | 89.8% |
| FCF Growth YoY | -4.8% | 113.5% |
| FCF/Sales | 13.6% | 19.7% |
| CapEx/Sales | 5.4% | 0.9% |
Operational Efficiency
| Metric | BIO | TXG |
|---|---|---|
| Asset Turnover | 0.25x | 0.60x |
| Receivables Turnover | 5.9x | 13.0x |
| Inventory Turnover | 1.6x | 3.5x |
| Fixed Assets Turnover | 5.0x | 2.9x |
| Days Sales Outstanding | 62 days | 28 days |
| Days Inventory | 229 days | 104 days |
| Payables Period | 42 days | 41 days |
| Cash Conversion Cycle | 249 days | 91 days |
Income Statement
| Metric | BIO | TXG |
|---|---|---|
| Total Revenue | $2.59B | $617M |
| Operating Income | $53M | -$88M |
| Net Income | $222M | -$75M |
| R&D Expense | $266M | $227M |
| SG&A Expense | $852M | $297M |
| Cost of Goods Sold | $1.25B | $185M |
Dividend & Shareholder Information
| Metric | BIO | TXG |
|---|---|---|
| Shares Outstanding | 27M | 130M |
| Net Income Growth | -30.3% | – |
| EPS Growth | -84.0% | – |
BIO vs TXG: stock comparison and AI forecast
Which is bigger, BIO or TXG?
BIO is 1.2 times larger than TXG by market capitalization ($10.02B against $8.03B).
Which one does Intratio's AI model rank higher, BIO or TXG?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.